China Resources Pharmaceutical raises RMB1.1 bn from first 2025 corporate bond tranche

China Resources Pharmaceutical Group Limited announced the completion of the first tranche of its 2025 corporate bonds, issued in the People's Republic of China. The offering, carried out by its wholly-owned subsidiary CR Pharmaceutical Holdings, raised RMB1.1 billion. These bonds have a three-year term and carry a coupon rate of 1.82% per annum. The issuance was approved by the China Securities Regulatory Commission for an aggregate principal amount of no more than RMB10 billion to qualified investors.

The net proceeds from this initial tranche will be allocated towards crucial production expenditures, including the repayment of corporate debts, replenishment of working capital, and funding project development and operation expenditures. Funds will also be invested in scientific and technological innovations and other purposes in compliance with relevant laws and regulations.

The board advises shareholders and potential investors to exercise caution when dealing in the company’s securities following this announcement. As of October 21, 2025, Mr. Bai Xiaosong chairs the board, which comprises executive, non-executive, and independent non-executive directors.